2021 Volume 80 Issue 5 Pages 225-231
The efficacy of a novel treatment, combination chemotherapy employing methotrexate, rituximab and otherantineoplastic agents with consolidation therapy via radiation therapy and cytarabine (R-MPV therapy), for primary central nervous system lymphoma has been reported in multiple studies. We introduced R-MPV therapy inJuly 2019 and performed it in 4 patients over a one-year period. We describe here the detailed clinical courses ofthese 4 patients. Although grade 3 or 4 neutropenia was observed in all patients, all elements of R-MPV therapywere performed in all 4 patients without critical side effects. Tumors recurred in 1 patient; however, completeremission has been maintained in 3 patients up until now. Although an additional effect on survival is expectedwith this novel treatment strategy, further long-term observations and evaluations are needed for R-MPV therapyto be established.
